Six hundred thousand women are waiting for gynaecology care in England. The bottleneck isn’t insight — it’s the referral that sits untriaged, the menopause consultation that overruns, the scan that waits three days for a report. That is infrastructure work, and it is what we already do.
Six stages from referral to longitudinal record. What is live in hospitals today is marked separately from what is in development.
Nothing here is a new product line. Every item below is an existing DeepInfinity agent running against women’s health case mix, with the vocabulary, templates and report structures of that specialty.
The national plan for the gynaecology backlog is to sort referrals at a single point of access and divert what doesn’t need secondary care. That is a triage-and-routing problem against unstructured referral letters.
Menopause, fertility and complex gynaecology appointments are narrative, symptom-heavy and run over. Ambient capture returns that time and produces a structured symptom record as a by-product.
Mammography, breast ultrasound and MRI, obstetric and gynaecological ultrasound. In our Indian government hospital deployments, obstetric ultrasound already makes up a substantial share of daily reported volume.
HPV primary screening and cytology reporting are high-volume, templated and repetitive — the conditions under which structured reporting agents pay for themselves fastest.
Antenatal clinic registration at volume, and escalation documentation for postpartum haemorrhage, pre-eclampsia and eclampsia. In India this maps directly onto a stated government priority in maternal outcomes.
Endometriosis and PCOS are still diagnosed in years, not weeks, because the symptom history is scattered across free-text notes from a dozen appointments. We already sit inside those appointments — and that history has to be collected before it can be learned from.
Investors in this category have been burned by app-shaped companies. Being clear about the edges of the proposition is part of the proposition.
Women’s health carries scrutiny that general clinical documentation does not. We would rather arrive with the answers than assemble them after the question.
Documentation sits outside medical device territory. Triage that influences referral priority does not — it likely falls to Class IIa under UK MDR. We treat that as a deliberate step rather than a feature release, under our named Clinical Safety Officer and DCB0129.
Special category data with a political charge attached. Our data protection impact assessment, retention rules and processing locations for this pathway are written to be read by an information governance lead, not a procurement portal.
Black women continue to face disproportionately poor maternal outcomes, and the most deprived areas carry a substantially higher gynaecology waiting list per head. Any deployment here is asked how performance holds across those groups.
UK regulatory scope. DeepInfinity Scribe is the product registered with the MHRA as a Class I medical device under UK MDR 2002. Imaging interpretation and scoring agents follow a Class IIa pathway and are not offered in the UK. Please confirm the current regulatory position of any individual agent with our regulatory team before relying on it in a procurement or tender response.
The fastest way to test this is a single women’s health hub: referral triage at the front door, ambient documentation inside the clinic, and a measured effect on time-to-first-appointment over a defined cohort. We can scope that in a fortnight.